[A24-85 ] Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2024
Project no.:
A24-85
Commission:
Commission awarded on 27.08.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-85
Project no. | Title | Status |
---|---|---|
A22-109 | Faricimab (visual impairment due to diabetic macular oedema) – Benefit assessment acc. to § 35a Social Code Book V | Commission completed |
A22-110 | Faricimab (neovascular age-related macular degeneration) – Benefit assessment according to § 35a Social Code Book V | Commission completed |